Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $12.2308.

A number of brokerages recently commented on CMPX. Lifesci Capital assumed coverage on Compass Therapeutics in a report on Monday, October 6th. They set an “outperform” rating and a $10.00 target price for the company. William Blair started coverage on Compass Therapeutics in a research report on Monday, January 5th. They set an “outperform” rating on the stock. Compass Point set a $10.00 target price on Compass Therapeutics in a report on Monday, October 6th. Citizens Jmp began coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 price target on the stock. Finally, JMP Securities set a $10.00 price objective on Compass Therapeutics in a research report on Wednesday, December 3rd.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Flagship Harbor Advisors LLC purchased a new stake in Compass Therapeutics during the fourth quarter worth approximately $32,000. Tema Etfs LLC acquired a new stake in Compass Therapeutics during the fourth quarter worth approximately $538,000. Avanza Fonder AB purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth approximately $147,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Compass Therapeutics during the 3rd quarter worth approximately $37,000. Finally, Vivo Capital LLC boosted its holdings in shares of Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $6.19 on Tuesday. Compass Therapeutics has a 1-year low of $1.33 and a 1-year high of $6.40. The firm has a market cap of $1.10 billion, a PE ratio of -13.76 and a beta of 1.45. The company has a 50-day moving average of $5.34 and a two-hundred day moving average of $4.18.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. Sell-side analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.